Vanguard Group Inc Viking Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $5.46 Trillion
- Q3 2024
A detailed history of Vanguard Group Inc transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 10,167,614 shares of VKTX stock, worth $430 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
10,167,614
Previous 10,097,337
0.7%
Holding current value
$430 Million
Previous $535 Million
20.26%
% of portfolio
0.01%
Previous 0.01%
Shares
13 transactions
Others Institutions Holding VKTX
# of Institutions
473Shares Held
65.6MCall Options Held
5.72MPut Options Held
3.39M-
Black Rock Inc. New York, NY6.03MShares$255 Million0.01% of portfolio
-
State Street Corp Boston, MA4.67MShares$198 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.12MShares$89.6 Million0.01% of portfolio
-
Morgan Stanley New York, NY1.87MShares$79.3 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA1.86MShares$78.9 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $3.25B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...